The Subretinal Fluid Tolerance Post Faricimab Injection Short Case Review Study

Aim: To evaluate the efficacy of a new Anti-VEGF molecules Faricimab 6 mg (0.05ml of 120mg/ml) in resolving a refractory subretinal fluid (SRF) in wet AMD cases. Method: We retrospectively reviewed a 64-year-old female Caucasian single eye patient, presented to our clinic on September 2019 with (wet AMD) in the right eye & advanced wet AMD with fibrosis and scar in the left eye. The patient decided to treat the right eye only, she received initially 3 loading doses of aflibercept (40 mg/ml) and then was shifted to a treat and extend regimen (T&E). Thew best corrected vision (BCA) has been improved from 0.5 to 0.8 with persistence of subretinal fluid during the treatment period. On her recent visit, the patient then shifted to Faricimab (Vabysmo 6mg). Result: The swept source OCT (SS-OCT) image one month post Faricimab injection showed a complete resolution of subretinal fluid with improvement of vision to all 0.8 + 2.